Ozempic slimming craze sweeps Kosovo despite side effects
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
'Constant demand'
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
Ozempic 'every day'
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
16 hours ago
- Euronews
Mental health innovations take centre stage at VivaTech Paris
VivaTech opened its doors this Wednesday in Paris, marking the start of Europe's most important tech and startup annual event. With more than 165,000 expected visitors and nearly 14,000 startups from over 50 countries, the ninth edition of the event is set to be the biggest yet. Just like last year, artificial intelligence (AI) is the star of the show. But this time, some of the most attention-grabbing innovations are those applying AI and tech to health care and mental well-being. 'Artificial intelligence is moving from science fiction to real-life application. And visitors will discover with the more than 13,000 start-ups what it is going to mean for business, for our everyday lives and our democracies," said François Bitouzet, Director General of VivaTech. There is a geopolitical context that is incredible in which tech and AI play a role, and we will analyse this during the next four days," he told Euronews. In a year marked by increasing geopolitical tensions and debates around technological sovereignty, Europe is looking to assert itself as a key player in AI innovation. But the tech fair also serves as a platform to explore how this technology can help address deeply human challenges. One such example is Emobot, a French startup developing an AI-powered tool that helps monitor mood disorders through a patient's facial expressions and voice. 'It's an app that is installed on the phone and on the computer. We analyse facial expressions every second while the patient uses their phone throughout the day," explained Antony Perzo, co-founder and CTO of Emobot. "We also analyse their voice. Then, we aggregate this data to monitor for symptoms of depression. All this data, we put it together and then make a dashboard for the doctor that allows them to follow the evolution of the mood disorder symptoms," he told Euronews. All this information is combined to generate a dashboard for doctors, allowing them to track the evolution of symptoms remotely. 'Psychiatry is one of the few disciplines where we can't visualise disorders. In other areas of medicine, we have MRIs or imaging tools. We wanted to create the first device capable of tracking and visualising mood symptoms over time. Think of it as a sort of thermometer for mental health', he said. Another mental health startup, AMOI, blends neuroscience with perfume to shift a person's mood in just minutes. Whether you're looking for focus, calm, energy or joy, AMOI claims its neuro-fragrances can deliver results within five minutes. With more than one in four people reporting feeling mentally unwell, AMOI's founder Pascale Fontaine, says her project is about offering accessible and enjoyable tools for emotional well-being. VivaTech runs until 14 June at the Porte de Versailles exhibition centre in Paris. The European debate on children's access to social media networks has begun, with three EU Member States promoting the idea of a "digital majority" or the age below which it would be forbidden to connect to such platforms. For France, Spain and Greece, the goal is to protect minors from dangerous online content. "Today, in the terms and conditions of use of these platforms, there is already a minimum age of 13," explains Clara Chappaz, the French Minister Delegate for Artificial Intelligence and the Digital Economy. However, Chappaz says: "We've all been children, it's very easy to change your date of birth. And so the current system means that, on average, children are logging on and creating accounts from the age of 7-8." France, Spain and Greece believe that the algorithms used by social networks expose the very young to addictive content that can ultimately lead to increased anxiety or depression. They also argue that excessive exposure may limit the development of certain skills and impair cognitive abilities. The EU currently has legislation in place in the form of the Digital Services Act (DSA), which tackles illegal online content such as hate speech, terrorism and child pornography. The law has been in place for almost two years for larger platforms and search engines, and just over a year for smaller organisations. But for industry representatives in Brussels, new legislation appears premature. "We believe that the new rules must first be properly applied. We haven't yet seen all the effects," says Constantin Gissler, Managing Director of Dot Europe, which represents online services and platforms in Brussels. "I think it's a bit hasty at this stage to be already discussing new rules and I think it's also very important that we take more account of the reality and implications for minors of such a ban," he adds. Paris, Madrid and Athens are also proposing the integration of age verification and parental control systems for devices connected to the Internet. The European Commission is currently working on an age verification application. Last month it published draft guidelines to protect minors, such as measures to verify the age of users or to set children's accounts as private by default. It is also conducting investigations against TikTok, Instagram and Facebook in relation to the protection of minors.
France 24
a day ago
- France 24
Gaza rescuers say Israeli fire kills 31 in latest deadly shooting near aid centre
The Gaza civil defence agency said 31 people were killed and "about 200" wounded Wednesday when Israeli troops fired on people waiting to enter a food distribution centre. "We transported at least 31 martyrs and about 200 wounded as a result of Israeli tank and drone fire on thousands of citizens... on their way to receive food from the American aid centre," civil defence spokesman Mahmud Bassal told AFP. The Israeli military had no immediate comment. Bassal said thousands of Palestinians had been gathering since 2am in the hope of reaching the US and Israeli-backed food distribution centre. "Israeli tanks fired several times, then at around 5:30 am intensified their fire, coinciding with heavy fire from drones targeting civilians," he said. Medical officials at Shifa and Al-Quds Hospitals said at least 25 people were killed as they approached the aid site near the former settlement of Netzarim, southwest of Gaza City. Ten other people were killed in other Israeli military strikes in Khan Younis in the south of the enclave, they added. Restrictions imposed on media in the Gaza Strip and the difficulties of access on the ground mean the death tolls could not be independently verified. There have been a series of deadly shootings since the Gaza Humanitarian Foundation (GHF) first opened aid distribution points in the Palestinian territory on May 27, as Israel faced mounting international condemnation over the humanitarian conditions. After similar incidents in recent days, the Israeli army said it fired warning shots to distance "suspects" who were approaching the troops and posed a threat. The war erupted after Hamas-led militants took 251 hostages and killed 1,200 people, most of them civilians, in an October 7, 2023, attack, Israel's single deadliest day. Israel's military campaign has since killed nearly 55,000 Palestinians, most of them civilians, according to health authorities in Gaza, and flattened most of the coastal enclave.
AFP
2 days ago
- AFP
Video misleads about safety of 6-in-1 vaccine Vaxelis
"A new vaccine is on the market for your 6 week old baby! It's never been tested against a placebo or for carcinogenic effects," claims a May 19, 2025 Instagram post from a Canadian content creator who regularly posts against vaccination. She is one of several creators who stitched their reactions next to a video with thousands of interactions from Jeffrey Barke, a founding member of America's Frontline Doctors -- a group AFP has repeatedly fact-checked. In the video, Barke reads from the package insert for Vaxelis, a shot given to simultaneously prevent infections caused by pertussis, diphtheria, tetanus, poliomyelitis, Haemophilus influenzae type b, and hepatitis B (archived here). "Studies that brought this product to market -- there is not a single randomized controlled study with an inert placebo. It's only tested against other vaccinations," he says, implying this is cause for concern. Image Screenshot of Instagram reels taken on June 3, 2025 Similar claims also appeared on X in French, German, Spanish and Croatian, spreading as officials with the US Department of Health and Human Services under Robert F. Kennedy, Jr. aim to shift the way vaccines are tested and approved. The posts also come as experts say vaccine misinformation is rampant online and may be contributing to falling vaccination rates across the United States and Canada (archived here and here). Vaxelis is not new, however. The US Food and Drug Administration first approved the joint venture of pharmaceutical companies Sanofi Pasteur and Merck for children six weeks through four years of age in December 2018 (archived here and here). It is also administered in Europe (archived here). Kelly Moore, president and CEO of the nonprofit co-authored the policy statement for Vaxelis from the US Advisory Committee on Immunization Practices (ACIP), a panel of experts that makes recommendations about the childhood vaccinations schedule (archived here). "It's an excellent vaccine," she told AFP in a June 2 email. In February 2019, the ACIP reported that Vaxelis was subjected to six clinical studies involving more than 5,000 infants six to 12 weeks of age (archived here). It said the studies showed Vaxelis "had an acceptable safety profile that is consistent with its component vaccines." Placebo testing Barke is correct that Vaxelis was not tested against an inert placebo. But experts said there is reason for that: it would have been unethical to do so. Clinical trial participants must be offered the existing standard of care, Moore said. It would be "entirely unethical" to withhold existing vaccines while testing a combination product that contains components already routinely given in those separate shots, she said. The World Health Organization has also pushed back against calls for changes to vaccination testing. "The safety of vaccines is held to an extremely high standard," WHO vaccine chief Kate O'Brien said May 1, 2025 (archived here). O'Brien stressed that the "gold standard" process calls for placebo testing when developing vaccines against diseases for which no immunization options exist. But when vaccines are developed to cover new strains or to offer a combination shot against multiple viruses, they are generally tested to see if they are as or more effective than the existing shots. O'Brien said it would also be unethical to give test subjects a placebo in place of "vaccines that are life-saving that are already licensed." Combination vaccines Barke further misleads by misinterpreting section 13.1 of the package insert, which says that Vaxelis was not evaluated for "carcinogenic or mutagenic potential or impairment of fertility." The language appears in documents for many routine vaccines, US health care group Novant Health explains on its website (archived here). "This merely means that there was no need for further testing because toxicology studies conducted at the preclinical phase showed no signs of adverse effects from the vaccine or its individual components," it says. There are also specific guidelines and rules for when a manufacturer needs to perform fertility studies. With a shot approved for use only in populations under five years old, studies in pregnant animals would not take place, said Kathryn Edwards, an expert in vaccinology at the Vanderbilt University Medical Center (archived here). "These vaccines have been used individually for decades in millions of people that there has not been a signal for infertility and no biologic reason why you would be concerned," she said in a June 4 email. Six-in-one shots, including Vaxelis, were developed to lower the number of injections for children, "reduce the burden of handling multiple different separate vaccines and to ensure timely administration of all the needed vaccines," Edwards said. The Canadian Paediatric Society and the Canadian National Advisory Committee on Immunization currently recommend children receive 5-in-1 or 6-in-1 vaccines (archived here and here). After a vaccine is approved, its safety continues to be monitored. "Combination vaccines have been shown to be no more reactive than separate vaccines, and no long term complications have been seen with combination vaccines," Edwards said. Such products have several advantages, including increased coverage rates, reduced need for additional health care visits and lower costs for distributing the product, according to the US Center for Disease Control and Prevention (archived here). Adverse effects Barke's video highlights the potential risk of Guillain-Barré syndrome -- a condition in which the body's immune system attacks the nerves, sometimes causing temporary paralysis. He also points to apnea, which is a pause in breathing, as a risk. But Edwards said Guillain-Barré syndrome is "very rare in children." Cedars Sinai Hospital says on its website that most children diagnosed with Guillain-Barré syndrome "recover fully with no complications" (archived here). Rachel Greenberg, associate professor of pediatrics at Duke University School of Medicine, researched apnea risks when vaccinating premature infants (archived here). "While there is a temporary increased risk of apnea after vaccination, the risk posed by vaccine-preventable respiratory and other infections to unvaccinated infants is far higher," she said in a press release about her January 2025 study (archived here). The most common side effects reported following a shot of Vaxelis are pain or swelling at the injection site and fever (archived here). Melody Butler, founding executive director of Nurses Who Vaccinate, said parents weighing the risk of rare, serious adverse events should remember how many children still die from vaccine-preventable diseases (archived here). "We've become so spoiled that we don't even know what these diseases do to the human body," she told AFP June 4. "We're very fortunate that we don't see these diseases firsthand." Ingredients Barke's video also targets the vaccine's ingredients, a tactic regularly deployed by activists who claim, without evidence, that immunizations are dangerous. In particular, he questions aluminum and formaldehyde. Aluminum is naturally found in the environment, and humans ingest it through drinking water and some foods, including breast milk and infant formula. Aluminum boosts immune response, reducing the amount of vaccine required to provide immunity (archived here). Aluminum-containing vaccines have been used for decades and have been administered to more than one billion people without problem, the Children's Hospital of Philadelphia (CHOP) says on its website (archived here). Formaldehyde, meanwhile, is "essential in human metabolism" and can be found in all humans, according to CHOP (archived here). It is used in vaccines to help prevent bacterial contamination during manufacturing (archived here). "There's more formaldehyde in a single apple or pear than in a vaccine," Butler said, dismissing the residual amounts passed to the body during vaccination as "negligible." Read more of AFP's reporting on vaccine misinformation here.
